Article
Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts.
Oncotarget - 13 Jun 2017
Slobbe Paul, Windhorst Albert D, Adamzek Kevin, Bolijn Marije, Schuit Robert C, Heideman Daniëlle A M, van Dongen Guus A M S, Poot Alex J
Abstract excerpt
Over the last decade kinase inhibitors have witnessed tremendous growth as anti-cancer drugs. Unfortunately, despite their promising clinical successes, a large portion of patients does not benefit from these targeted therapeutics. Vemurafenib is a serine/threonine kinase inhibitor approved for the treatment of melanomas specifically expressing the BRAFV600E mutation. The aim of this study was to develop...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.